Monimus Capital Management LP Takes $664,000 Position in Assembly Biosciences, Inc. (NASDAQ:ASMB)

Monimus Capital Management LP purchased a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 42,067 shares of the biopharmaceutical company’s stock, valued at approximately $664,000. Monimus Capital Management LP owned approximately 0.66% of Assembly Biosciences as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 3,442 shares in the last quarter. Palumbo Wealth Management LLC bought a new position in shares of Assembly Biosciences during the 4th quarter worth approximately $180,000. FMR LLC raised its stake in shares of Assembly Biosciences by 29.7% during the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 3,635 shares in the last quarter. Finally, Peapod Lane Capital LLC bought a new position in shares of Assembly Biosciences during the 4th quarter worth approximately $994,000. Institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Price Performance

Shares of NASDAQ ASMB opened at $10.86 on Friday. The company’s fifty day moving average price is $13.51 and its 200 day moving average price is $15.34. Assembly Biosciences, Inc. has a 1 year low of $10.56 and a 1 year high of $19.93.

Insider Activity at Assembly Biosciences

In related news, Director Michael Houghton bought 3,202 shares of the stock in a transaction on Monday, December 30th. The stock was bought at an average price of $15.61 per share, with a total value of $49,983.22. Following the completion of the purchase, the director now directly owns 3,202 shares in the company, valued at $49,983.22. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 5.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research report on Friday, December 27th.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.